Livagen

Livagen is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala, single-letter code KEDA). Molecular weight is 461.47 g/mol. It belongs to the Khavinson Cytogen class and is positioned as a liver and immune-system bioregulator. The compound was developed from analysis of polypeptide liver complex extracts (Ventvil) at the St. Petersburg Institute of Bioregulation and Gerontology.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures. Cytogens are short synthetic peptides designed to reproduce single defined active sequences. For the liver, the broader Khavinson liver peptide complex (Ventvil) is the Cytomax, with Svetinorm marketed as a related liver Cytomax. Livagen represents the synthetic Cytogen derived from the liver peptide complex.

The KEDA sequence shares the KED motif with Testagen (KEDG, testicular) and Vesugen (KED, vascular), differing in the C-terminal residue. This pattern raises legitimate questions about tissue-specificity claims, as the KED core appears across multiple Khavinson Cytogens with claimed targeting of distinct organ systems.

The Evidence

The compound-specific evidence base consists of:

Chromatin decondensation work. The most distinctive published finding for Livagen is its effect on chromatin structure in cell culture. In lymphocytes from elderly donors, the cells display progressive heterochromatinization with aging (pathological condensation of ribosomal gene clusters and pericentromeric regions). Livagen treatment decondenses this aged heterochromatin, reactivating ribosomal genes and restoring transcriptional activity to patterns characteristic of younger cells. The mechanism work parallels findings reported for other Khavinson tetrapeptides.

Enzyme modulation (Kost et al., 2003). Livagen and Epitalon were both shown to modulate enkephalin-degrading enzymes in human serum, with implications for opioid peptide pathway signaling.

Hepatoprotective effects (Khavinson 2020 review). Animal experimental models of liver fibrosis, acute hepatitis, and chronic hepatitis reported high efficacy of both Livagen and the parent Ventvil liver polypeptide complex in restoring liver function markers, with maximum effects observed in aging animals.

Russian institutional observational data. Use in elderly populations with hepatic dysfunction and immune complaints has been described in Russian-language clinical reports without rigorous controlled trial methodology.

Independent Western confirmation is sparse. PubMed indexing returns predominantly Khavinson-affiliated publications. No registered ClinicalTrials.gov trial exists for Livagen as of May 2026.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval.

Russia. Sold as a biologically active dietary supplement.

WADA. Not on 2026 Prohibited List.

The proposed mechanism centers on chromatin remodeling and gene-expression effects.

Chromatin decondensation. Livagen's most distinctive characterized effect is the reversal of age-associated heterochromatinization. In aged lymphocytes, ribosomal gene clusters and pericentromeric heterochromatin become pathologically condensed, reducing transcriptional accessibility. Livagen exposure produces decondensation of these regions, restoring chromatin to a state more characteristic of younger cells. The mechanism is hypothesized to involve direct peptide-DNA or peptide-histone interactions, consistent with the broader Khavinson short-peptide bioregulation framework.

Cellular entry and nuclear localization. KEDA is hypothesized to enter cells through peptide transporters (PEPT1, PEPT2), reach the cytoplasm, and translocate to the nucleus. The small molecular weight facilitates passive diffusion through nuclear pores.

Downstream gene-expression effects. Reactivation of ribosomal genes increases ribosomal RNA synthesis and translational capacity. The cellular consequence is increased protein synthesis activity, particularly relevant in aged cells where this capacity has declined. The KEDA tetrapeptide has been reported to:

• Decondense pericentromeric heterochromatin in aged lymphocytes
• Reactivate ribosomal gene transcription
• Restore protein synthesis rates in aged hepatocyte cultures
• Modulate inflammatory and stress-response gene expression
• Affect liver-specific protein synthesis markers

Pharmacokinetics. Oral tetrapeptides face gut hydrolysis. The Khavinson framework proposes signaling at the gut-mucosa interface propagated systemically through neural and humoral pathways. Direct measurement of intact Livagen in plasma after oral administration has not been published.

Human pharmacokinetic data is not published.

Cell culture and Russian observational data report:

• Chromatin decondensation in aged lymphocytes with ribosomal gene reactivation
• Restoration of protein synthesis rates in aged hepatocyte cultures
• Hepatoprotective effects in animal liver fibrosis and hepatitis models
• Immunoprotective effects in aging animal models
• Modulation of enkephalin-degrading enzyme activity
• Possible adjunct effects in chronic liver dysfunction protocols

Research-chemical user reports describe subjective improvements in digestive function, energy, and general well-being. Reports are uncontrolled and unverified. The chromatin-effects framing is mechanistically interesting but extrapolating from cell-culture chromatin changes to clinical aging reversal is a substantial leap that has not been validated.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Livagen.

Russian retail Livagen is dosed as 1 to 2 capsules once or twice daily before meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 20 mg of active peptide.

Research-chemical Livagen is sold as lyophilized powder. Subcutaneous protocols typically use 100 to 500 mcg per day over 10 to 20 day cycles. These doses are extrapolated from generic Khavinson recommendations and lack Livagen-specific human pharmacokinetic support.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation lists individual intolerance, pregnancy, and lactation as contraindications.

The constituent amino acids (lysine, glutamic acid, aspartic acid, alanine) are common dietary amino acids. Tetrapeptide doses at the microgram-to-milligram level fall within typical dietary peptide exposure.

Long-term human safety data with controlled endpoints does not exist. Theoretical concerns specific to chromatin-modifying compounds:

• Effects on transcriptional homeostasis with chronic high-dose use are uncharacterized
• Effects in patients with active liver disease (cirrhosis, hepatocellular carcinoma) have not been formally evaluated
• The decondensation effects on chromatin could theoretically affect oncogene expression in predisposed individuals; this concern has not been formally addressed
• Drug-drug interactions with medications metabolized through hepatic CYP enzymes have not been studied; theoretical effects on CYP-relevant gene expression are unknown
• Effects in patients on immunosuppressive therapy have not been evaluated

The compound's gene-expression-modifying claims, if accurate, would warrant more careful long-term safety evaluation than has been performed.

Within the Khavinson system, Livagen is the synthetic Cytogen for the liver axis. The standard Cytogen-then-Cytomax sequence pairs Livagen with Svetinorm (liver Cytomax) for extended support.

For broader gastrointestinal and detoxification stacks, Livagen combines with:

• Ovagen (EDL tripeptide, liver/GI Cytogen)
• Svetinorm (liver Cytomax)
• Suprefort (pancreas Cytomax)
• Thymalin (immune Cytomax for combined immune-hepatic protocols)

For broader geroprotective protocols, Livagen joins Epitalon (pineal) and other organ-specific bioregulators. The chromatin decondensation effects reported for Livagen, Epitalon, and other Khavinson tetrapeptides have been used to position these compounds as "epigenetic age reversal" candidates in marketing materials, though independent confirmation of clinically meaningful epigenetic aging effects is absent.

External pharmaceutical comparators for liver disease have substantial Phase 3 evidence bases for specific indications:

• Direct-acting antivirals for hepatitis C (achieving cure rates >95 percent in most patient populations)
• Tenofovir and entecavir for hepatitis B
• Obeticholic acid for primary biliary cholangitis
• Resmetirom for non-alcoholic steatohepatitis (recently approved)
• Liver transplantation for end-stage disease

Livagen has no comparable evidence base for any specific liver indication and is not a substitute for evidence-based hepatology care in clinically significant liver disease.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.